News

Sanofi (NASDAQ:SNY) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 30, Sanofi (NASDAQ:SNY) announced that ...
Sanofi (NASDAQ:SNY) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On June 25, Sanofi (NASDAQ:SNY) ...
Sanofi (NASDAQ:SNY) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 30, Sanofi (NASDAQ:SNY) announced that its Riliprubart has been granted orphan drug designation in Japan for ...
On June 25, Sanofi (NASDAQ:SNY) announced that the FDA granted orphan drug designation to Riliprubart for treating antibody-mediated rejection in solid organ transplantation.
The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.
The table below is a review of notable updates that occurred in June 2025 for investigational products in development (not an inclusive list). Click on ...
Riliprubart Earns Orphan Drug Designation in the US for Antibody-mediated Rejection in Solid Organ Transplantation This designation reflects Sanofi’s commitment to addressing a critical unmet need in ...